{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '1.1.', 'Protocol Approval Signature Page', 'Protocol No:', 'BCX7353-301 (APeX-J)', 'Protocol Title:', 'A Phase 3, randomized, double-blind, placebo-controlled, parailel-group study', 'to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral', 'treatment for the prevention of attacks in subjects with hereditary angioedema', 'Date:', 'Version 6.0: 07 August 2020', 'BioCryst Pharmaceuticals, Inc.', 'Reviewed and Approved by:', 'William P. Shinde', '11 AUG 2020', 'for Melanie Compropst, PharmD, PhD', 'cm:/see', 'Date', 'Vice President, Clinical Development', 'BioCryst Pharmaceuticals, inc.', 'Sylvif Dobo, MD', 'A', 'HAUG 2020', 'Date', 'Vice President, Medical & Safety', 'BioCryst Phermaceuticals, Inc.', 'illunBBy', '11 ANG 2020', 'Ellion Berger, PhD', 'Date', 'Senior Vice President, Regulatory Affairs', 'BioCryst Pharmaceuticals, Inc.', 'OrphanPacilie, Inc.', 'Reviewed and Approved by:', '13 AUG 2020', 'Yoshly Yonemoto', 'Date', 'Director, Department of Clinical Development', 'OrphanPacific, inc.', '4']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '1.2.', 'Clinical Study Protocol Agreement', 'Protocol No:', 'BCX7353-301 (APeX-J)', 'Protocol Title:', 'A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study', 'to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral', 'treatment for the prevention of attacks in subjects with hereditary angioedema', 'Date:', 'Version 6.0: 07 August 2020', 'I have carefully read this protocol and agree that it contains all of the necessary information', 'required to conduct this study. I agree to conduct this study as described and according to the', 'Declaration of Helsinki, International Council for Harmonisation guidelines for Good Clinical', 'Practice, and all applicable regulatory requirements.', \"Investigator's Signature\", 'Date', 'Name (Print)', '5']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '2.', 'SYNOPSIS', 'Name of Sponsor/Company:', 'BioCryst Pharmaceuticals, Inc. (BioCryst)', 'After BCX7353 marketing authorization in Japan:', 'OrphanPacific, Inc.', 'BioCryst will continue to oversee the clinical conduct of the post-marketing study.', 'Name of Investigational Product:', 'BCX7353 (berotralstat)', 'Name of Active Ingredient:', '(R)-1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-', 'fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide', 'Title of Study:', 'A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the', 'efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks', 'in subjects with hereditary angioedema (Study BCX7353-301)', 'Study centers: Approximately 15 centers in Japan', 'Enrollment period: Approximately 3 months', 'Phase of development: 3', 'Part 1 Primary Objective:', 'To determine the efficacy of BCX7353 110 and 150 mg administered once daily (QD) for', '24 weeks compared to placebo in the prevention of angioedema events in subjects with', 'hereditary angioedema (HAE)', 'Part 1 Secondary Objectives:', 'To assess the safety and tolerability of BCX7353 110 and 150 mg QD administered for', '24 weeks', 'To assess the effects of BCX7353 on HAE disease activity and angioedema event', 'characteristics', 'To evaluate the effects of BCX7353 on quality of life (QoL)', 'To characterize the pharmacodynamic (PD) effects of BCX7353', 'Part 1 Primary Efficacy Endpoint:', 'The rate of expert-confirmed angioedema events during dosing in the entire 24-week', 'treatment period (Days 1 to 168).', 'Part 1 Secondary Efficacy Endpoints:', 'Change from baseline in Angioedema Quality of Life questionnaire (AE-QoL) at', 'Week 24 (total score)', 'Number and proportion of days with angioedema symptoms through 24 weeks', '6']\n\n###\n\n", "completion": "END"}